Rapport Therapeutics (RAPP) Cash & Equivalents (2023 - 2026)

Rapport Therapeutics (RAPP) has 4 years of Cash & Equivalents data on file, last reported at $476.8 million in Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $476.8 million, up 727.72% year-over-year; the trailing twelve-month figure through Mar 2026 was $476.8 million (up 727.72% YoY), and the FY2025 annual result was $52.6 million, down 7.32% from the prior year.
• Cash & Equivalents grew to $476.8 million in Q1 2026 per RAPP's latest filing, from $52.6 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $476.8 million in Q1 2026 and troughed at $39.3 million in Q3 2024.
• A 4-year average of $140.7 million and a median of $76.9 million in 2023 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2024 and 2026: Cash & Equivalents tumbled 75.34% in 2024, then surged 727.72% in 2026.
• A 4-year view of Cash & Equivalents shows it stood at $70.2 million in 2023, then declined by 19.05% to $56.8 million in 2024, then decreased by 7.32% to $52.6 million in 2025, then soared by 805.69% to $476.8 million in 2026.
• Business Quant data shows RAPP's Cash & Equivalents at $476.8 million in Q1 2026, $52.6 million in Q4 2025, and $251.4 million in Q3 2025.